Yen-Der Li's questions to Kura Oncology Inc (KURA) leadership • Q4 2024
Question
Yen-Der Li, on behalf of Jonathan Chang at Leerink Partners, asked about the company's confidence in achieving a long treatment duration for ziftomenib in frontline AML. He also questioned the protocol for mitigating potential imbalances in consolidation treatments within the KOMET-017 trial.
Answer
CMO Dr. Mollie Leoni cited data from the KOMET-007 trial showing prolonged use of ziftomenib, which informed their confidence. CCO Brian Powl added that an 18-24 month duration supports a potential $7 billion market. Dr. Leoni also explained the KOMET-017 trial is designed and powered with sensitivity analyses to account for any treatment imbalances between arms.